Ascendis Pharma Statistics
Total Valuation
Ascendis Pharma has a market cap or net worth of $10.59 billion. The enterprise value is $10.95 billion.
Important Dates
The next estimated earnings date is Tuesday, September 2, 2025, after market close.
| Earnings Date | Sep 2, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Ascendis Pharma has 60.55 million shares outstanding. The number of shares has increased by 3.88% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 60.55M |
| Shares Change (YoY) | +3.88% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 0.78% |
| Owned by Institutions (%) | 83.55% |
| Float | 60.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.76 |
| Forward PS | 13.42 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 27.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.04
| Current Ratio | 1.04 |
| Quick Ratio | 0.67 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.08 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -22.39% |
| Return on Invested Capital (ROIC) | -38.34% |
| Return on Capital Employed (ROCE) | -189.75% |
| Revenue Per Employee | $391,848 |
| Profits Per Employee | -$363,125 |
| Employee Count | 1,017 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 0.21 |
Taxes
In the past 12 months, Ascendis Pharma has paid $3.67 million in taxes.
| Income Tax | 3.67M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +27.36% in the last 52 weeks. The beta is 0.37, so Ascendis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +27.36% |
| 50-Day Moving Average | 168.33 |
| 200-Day Moving Average | 146.77 |
| Relative Strength Index (RSI) | 53.93 |
| Average Volume (20 Days) | 429,411 |
Short Selling Information
| Short Interest | 2.26M |
| Short Previous Month | 2.69M |
| Short % of Shares Out | 5.35% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.49 |
Income Statement
In the last 12 months, Ascendis Pharma had revenue of $398.51 million and -$369.30 million in losses. Loss per share was -$6.29.
| Revenue | 398.51M |
| Gross Profit | 339.92M |
| Operating Income | -360.82M |
| Pretax Income | -539.03M |
| Net Income | -369.30M |
| EBITDA | -355.41M |
| EBIT | -360.82M |
| Loss Per Share | -$6.29 |
Full Income StatementBalance Sheet
The company has $559.80 million in cash and $915.77 million in debt, giving a net cash position of -$355.98 million or -$5.88 per share.
| Cash & Cash Equivalents | 559.80M |
| Total Debt | 915.77M |
| Net Cash | -355.98M |
| Net Cash Per Share | -$5.88 |
| Equity (Book Value) | -205.15M |
| Book Value Per Share | -3.40 |
| Working Capital | 38.89M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$236.63 million and capital expenditures -$2.09 million, giving a free cash flow of -$258.16 million.
| Operating Cash Flow | -236.63M |
| Capital Expenditures | -2.09M |
| Free Cash Flow | -258.16M |
| FCF Per Share | -$4.26 |
Full Cash Flow StatementMargins
Gross margin is 85.30%, with operating and profit margins of -90.54% and -92.67%.
| Gross Margin | 85.30% |
| Operating Margin | -90.54% |
| Pretax Margin | -91.75% |
| Profit Margin | -92.67% |
| EBITDA Margin | -89.19% |
| EBIT Margin | -90.54% |
| FCF Margin | n/a |
Dividends & Yields
Ascendis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.88% |
| Shareholder Yield | -3.88% |
| Earnings Yield | -3.49% |
| FCF Yield | -2.44% |
Dividend DetailsAnalyst Forecast
The average price target for Ascendis Pharma is $222.18, which is 27.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $222.18 |
| Price Target Difference | 27.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (5Y) | 51.05% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascendis Pharma has an Altman Z-Score of -0.59 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.59 |
| Piotroski F-Score | 3 |
